Predict your next investment

HEALTHCARE | Drug Development
akelosinc.com

See what CB Insights has to offer

Founded Year

2018

Stage

Unattributed - II | Alive

Total Raised

$330K

Last Raised

$30K | 3 yrs ago

About Akelos

Akelos is a biopharmaceutical company focused on the translation of science into treatment. The company is developing non-narcotic drugs for the treatment of neuropathic pain.

Akelos Headquarter Location

40 Park Ave Suite 6

New York, New York, 10016,

United States

212-953-1544

Latest Akelos News

Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone

Mar 4, 2021

Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone NEW YORK - March 4, 2021 - ( Newswire.com ) Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, announces the lead compound AKE-1018 significantly reduces neuropathic pain in preclinical testing. Akelos's oral lead compound AKE-1018, at 10-times the lowest effective antihyperalgesic dose tested, does not affect heart rate, blood pressure, motor strength/coordination, is non-sedating, and lacks the potential for abuse. These results provide evidence of an excellent safety profile. AKE-1018 has been previously been shown to significantly reduce hypersensitivity to both mechanical and thermal noxious stimuli. This response was equivalent in both male and female adult rats and was seen as early as with a single dose, and which improved with additional daily dosing over a seven-day period. Dr. Dianna Willis, Co-Director of the Center for Pain and Sensory recovery at the Burke Neurological Institute (White Plains, NY), Assistant Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine (New York, NY) and lead investigator on these studies, observed: "These results clearly support the continued effort to develop AKE-1018 into a novel, non-opiate treatment for peripheral neuropathic pain." Akelos Inc. is in a research collaboration with Weill Cornell Medicine to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Dr. Goldstein is a patent owner and scientific advisory board member of Akelos, Inc. For more information, please contact: Akelos Inc. drstevefox@akelosinc.com Akelos Inc. Forward-Looking Statement: This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations; and market opportunity and competition. The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Press Release Service by Newswire.com PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. follow us Version: 2021.2.23.1 You are leaving PharmiWeb.com Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites. ABOUT THIRD PARTY LINKS ON OUR SITE PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com. PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly. Continue

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Akelos

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Akelos is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Akelos Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Akelos Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.